Inhibidores de receptores JAK quinasa e infección por virus varicela zoster en pacientes con artritis reumatoide. Revisión sistemática de la literatura / JAK Kinase Inhibitors and Varicella Zoster Virus Infection in Patients with Rheumatoid Arthritis. Systematic Review of the Literature

Objetivos: El objetivo de esta revisión sistemática es evaluar la infección por herpes zoster (HZ) publicada en los ensayos clínicos faseII y faseIII de pacientes con AR en tratamiento con inhibidores de JAK (iJAK). Material y métodos: Revisión sistemática de la literatura que evalúa la incidencia de HZ publicada en los ensayos clínicos de los distintos iJAK comercializados o en estudio. Resultados: Las tasas de HZ variaron entre el 1,51 y 20,22. Los resultados se expresaron principalmente en porcentaje de eventos. Los estudios más recientes categorizaron mejor la incidencia de HZ y su gravedad. Conclusión: Los iJAK se asocian a mayor riesgo de HZ. Aunque las tasas de HZ de los iJAK selectivos de JAK1 son menores, son necesarios más estudios que confirmen estos resultados.(AU)

Objectives: JAK kinase inhibitors (JAKi) are a new therapeutic option in the treatment of rheumatoid arthritis, but they are not without risks, especially the incidence of herpes zoster (HZ). Material and methods: Systematic literature review that evaluates the incidence of HZ published in the clinical trials of the different JAKis marketed or under study. Results: The HZ rates ranged between 1.51 and 20.22. The results were expressed mainly as a percentage of events. The most recent studies better categorized the incidence of HZ and its severity. Conclusion: JAKis are associated with an increased risk of HZ. Although the HZ rates of the selective JAK1 JAKis are lower, more studies are needed to confirm these results.(AU)

JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature.

OBJECTIVES: JAK kinase inhibitors (JAKi) are a new therapeutic option in the treatment of rheumatoid arthritis, but they are not without risks, especially the incidence of herpes zoster (HZ). MATERIAL AND METHODS: Systematic literature review that evaluates the incidence of HZ published in the clinical trials of the different JAK is marketed or under study. RESULTS: The HZ rates ranged between 1.51 and 20.22. The results were expressed mainly as a percentage of events. The most recent studies better categorized the incidence of HZ and its severity. CONCLUSION: JAK is are associated with an increased risk of HZ. Although the HZ rates of the selective JAK1 JAK is are lower, more studies are needed to confirm these results.